{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:09:16Z","timestamp":1770106156236,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jchf.2025.102891","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:04:42Z","timestamp":1770059082000},"page":"102891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Could Mineralocorticoid Receptor Antagonists Be Harmful in Some Patients With Heart Failure?"],"prefix":"10.1016","volume":"14","author":[{"given":"Jeffrey M.","family":"Testani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jchf.2025.102891_bib1","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102891_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102891_bib3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(88)90742-8","article-title":"Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor","volume":"2","author":"Edwards","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.102891_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2025.102891_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","article-title":"11Beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response","volume":"25","author":"Tomlinson","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jchf.2025.102891_bib6","first-page":"135","article-title":"11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess","volume":"18","author":"White","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jchf.2025.102891_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106541","article-title":"The multifaceted role of the mineralocorticoid receptor in cancers","volume":"242","author":"Doan","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.jchf.2025.102891_bib8","article-title":"Brain mineralocorticoid and glucocorticoid receptor balance in neuroendocrine regulation and stress-related psychiatric etiopathologies","volume":"24","author":"de Kloet","year":"2022","journal-title":"Curr Opin Endocr Metab Res"},{"key":"10.1016\/j.jchf.2025.102891_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00018-023-04900-x","article-title":"Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells","volume":"80","author":"Clarisse","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jchf.2025.102891_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrn1683","article-title":"Stress and the brain: from adaptation to disease","volume":"6","author":"de Kloet","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jchf.2025.102891_bib11","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.102673599","article-title":"Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes","volume":"99","author":"Beggah","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2025.102891_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ Res"},{"issue":"577","key":"10.1016\/j.jchf.2025.102891_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau9685","article-title":"Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice","volume":"12","author":"Oakley","year":"2019","journal-title":"Sci Signal"},{"key":"10.1016\/j.jchf.2025.102891_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","article-title":"Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone","volume":"79","author":"Maeoka","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2025.102891_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102891_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.02.025","article-title":"Interaction between aldosterone and mineralocorticoid receptor antagonist: findings from the EPHESUS trial","volume":"13","author":"Kobayashi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102891_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102670","article-title":"Aldosterone, subclinical cardiac dysfunction, and heart failure subtypes: the Jackson Heart Study","volume":"13","author":"Agoons","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102891_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925008212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925008212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:33:06Z","timestamp":1770060786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925008212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2213177925008212"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102891","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could Mineralocorticoid Receptor Antagonists Be Harmful in Some Patients With Heart Failure?","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102670","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102848","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}],"article-number":"102891"}}